BriaCell CEO Letter to Shareholders

Provided By GlobeNewswire

Last update: May 20, 2025

PHILADELPHIA and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to issue a letter to shareholders from Dr. William V. Williams, BriaCell’s President and CEO.